Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug

4 hours ago 2

• Healthcare
• On the Move

Eoneren

Rallybio (NASDAQ:RLYB) shares climbed ~114% in the premarket on Tuesday after the company announced an agreement to sell its ownership interest in REV102, a preclinical asset targeting a rare bone disorder called hypophosphatasia, to its joint venture partner Recursion Pharmaceuticals (

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug